Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies

Rheumatology International

Volumn 36, Issue 5, 2016, Pages 603-612

  Elyoussfi, Sarah ^a   Thomas, Benjamin J ^a   Ciurtin, Coziana ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Biologic treatments; Level of evidence of biologic agents efficacy; Psoriasis; Psoriatic arthritis; Small molecule inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; ANTIRHEUMATIC AGENT; APREMILAST; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; BRODALUMAB; CERTOLIZUMAB PEGOL; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ITOLIZUMAB; IXEKIZUMAB; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; USTEKINUMAB; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR;

ARTHRITIS; BIOLOGICAL THERAPY; CLINICAL FEATURE; DACTYLITIS; DRUG EFFICACY; ENTHESITIS; HUMAN; IMMUNOTHERAPY; META ANALYSIS (TOPIC); NAIL DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; PERSONALIZED MEDICINE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; HUMANS; INTERLEUKINS; PRECISION MEDICINE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958745036     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-016-3436-0     Document Type: Review

References (98)

1. Gladman DD, Mease PJ (2006) Towards international guidelines for the management of psoriatic arthritis. J Rheumatol 33(7):1228–1230
2. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D et al (2012) European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71(1):4–12
3. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K et al (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71(3):319–326
4. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG et al (2008) Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58(1):106–115
5. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289
6. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA et al (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34(5):1040–1050
7. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL et al (2007) Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatol Treat 18(6):341–350
8. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J (2007) Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the adalimumab effectiveness in psoriatic arthritis trial. Ann Rheum Dis 66(2):163–168
9. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP et al (2008) Efficacy and safety results from the randomized controlled comparative study of adalimumab versus methotrexate versus placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158(3):558–566
10. Karanikolas GN, Koukli EM, Katsalira A, Arida A, Petrou D, Komninou E et al (2011) Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 38(11):2466–2474
11. Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F et al (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29(4):399–403
12. Fenix-Caballero S, Alegre-del Rey EJ, Castano-Lara R, Puigventos-Latorre F, Borrero-Rubio JM, Lopez-Vallejo JF (2013) Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 38(4):286–293
13. Thorlund K, Druyts E, Avina-Zubieta JA, Mills EJ (2012) Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biol Targets Ther 6:417–427
14. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, Rodevand E et al (2013) Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 72(11):1840–1844
15. Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO registry. Arthritis Rheum 65(5):1213–1223
16. Gladman DD, Investigators AS, Sampalis JS, Illouz O, Guerette B (2010) Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 37(9):1898–1906
17. Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R et al (2011) Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 147(4):429–436
18. Van den Bosch F, Manger B, Goupille P, McHugh N, Rodevand E, Holck P et al (2010) Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 69(2):394–399
19. Manger B, Lorenz H, Sprekeler R (2008) Adalimumab (Humira) improves the signs and symptoms of joint, skin and nail manifestations of psoriatic arthritis (PsA): results from a German database of PsA patients receiving adalimumab. Ann Rheum Dis 67(Suppl II):528
20. Rigopoulos D, Gregoriou S, Lazaridou E, Belyayeva E, Apalla Z, Makris M et al (2010) Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol JEADV 24(5):530–534
21. Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS (2015) Treatment of nail psoriasis: best practice recommendations from the medical board of the national psoriasis foundation. JAMA Dermatol 151(1):87–94
22. Braun J, Rudwaleit M, Kary S, Kron M, Wong RL, Kupper H (2010) Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Rheumatology 49(8):1578–1589
23. Cohen Barak E, Kerner M, Rozenman D, Ziv M (2015) Combination therapy of cyclosporine and anti-tumor necrosis factor alpha in psoriasis: a case series of ten patients. Dermatol Ther 28(3):126–130
24. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227):385–390
25. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139(12):1627–1632; discussion 32
26. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A et al (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349(21):2014–2022
27. Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D et al (2005) Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 153(6):1192–1199
28. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM et al (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152(6):1304–1312
29. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367(9504):29–35
30. van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A et al (2008) Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 159(5):1177–1185
31. Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L et al (2009) Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 219(3):239–249
32. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264–2272
33. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al (2006) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33(4):712–721
34. Lubrano E, Spadaro A, Marchesoni A, Olivieri I, Scarpa R, D’Angelo S et al (2011) The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A 12 months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 29(1):80–84
35. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD et al (2010) Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340:c147
36. Ortonne JP, Paul C, Berardesca E, Marino V, Gallo G, Brault Y et al (2013) A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 168(5):1080–1087
37. Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J et al (2009) Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol JEADV 23(8):896–904
38. Torii H, Nakagawa H (2010) Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 59(1):40–49
39. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227–1236
40. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366(9494):1367–1374
41. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C et al (2007) A randomized comparison of continuous versus intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56(1):31e1–31e15
42. Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT et al (2006) Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 65(4):471–477
43. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT et al (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66(4):498–505
44. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C et al (2007) Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through 1 year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 56(8):2698–2707
45. Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H et al (2011) Efficacy and safety of infliximab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 165(5):1109–1117
46. Baranauskaite A, Raffayova H, Kungurov NV, Kubanova A, Venalis A, Helmle L et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71(4):541–548
47. Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK et al (2012) The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol 67(4):642–650
48. Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C et al (2012) Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 167(1):180–190
49. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D et al (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73(1):48–55
50. Mease PJ, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, Stach C et al (2014) 210. Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure. Rheumatology 53(suppl 1):i137–i138
51. Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ (2014) Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res 66(7):1085–1092
52. Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P (2015) Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis 74(1):44–51
53. van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D, Woltering F et al (2014) Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 73(1):233–237
54. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60(4):976–986
55. Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D et al (2014) Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 73(9):1689–1694
56. Kavanaugh A, Mease P (2012) Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol Suppl 89:90–93
57. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP et al (2011) Abatacept in the treatment of patients with psoriatic arthritis: results of a 6-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 63(4):939–948
58. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J et al (2011) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 70(6):1108–1110
59. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN et al (2002) A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47(6):821–833
60. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE et al (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139(6):719–727
61. Ortonne JP (2003) Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol JEADV 17(Suppl 2):12–16
62. Feldman SR, Menter A, Koo JY (2004) Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 150(2):317–326
63. Mease PJ, Gladman DD, Keystone EC, Alefacept in Psoriatic Arthritis Study G (2006) Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 54(5):1638–1645
64. Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ (2007) Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 11(2):57–66
65. Lotti T, Chimenti S, Katsambas A, Ortonne JP, Dubertret L, Licu D et al (2010) Efficacy and safety of efalizumab in patients with moderate-to-severe plaque psoriasis resistant to previous anti-psoriatic treatment: results of a multicentre, open-label, phase IIIb/IV trial. Arch Drug Inf 3(1):9–18
66. Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK et al (2014) Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol 71(3):484–492
67. Dogra S, Budamakuntla L, Srinivas CR, Khopkar U, Gupta S et al (2015) Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: a double-blind, randomized-withdrawal, placebo-controlled study. J Am Acad Dermatol 73(2):331
68. Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR et al (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64(10):3156–3167
69. Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD et al (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73(6):1020–1026
70. Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT et al (2012) Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 380(9843):738–746
71. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665–1674
72. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675–1684
73. Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK et al (2011) Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63(3):154–163
74. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B et al (2012) Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 166(4):861–872
75. Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S et al (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990–999
76. McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894):780–789
77. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C et al (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664):633–640
78. Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB (2010) Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin 26(10):2385–2392
79. Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S et al (2014) Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 73(6):1000–1006
80. Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y et al (2014) Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol 170(2):398–407
81. Young MS, Horn EJ, Cather JC (2011) The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Rev Clin Immunol 7(1):9–13
82. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K et al (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371(4):326–338
83. Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S et al (2015) Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 29(6):1082–1090
84. Thaci D, Humeniuk J, Frambach Y, Bissonnette R, Goodman JJ, Shevade S et al (2015) Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol
85. Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D et al (2014) Secukinumab, a human anti–interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, Placebo-Controlled Study. ACR 2014; Boston
86. McInnes I, Mease P, Kirkham B, Kavanaugh A, Ritchlin C, Rahman P et al (2014) Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis: 24-week efficacy and safety data from a phase 3 randomized, multicenter, double-blind, Placebo-Controlled Study using subcutaneous dosing. ACR 2014; Boston
87. van der Heijde D, Landewé R, Mease P, McInnes I, Conaghan P, Pricop L et al (2014) Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, Placebo-Controlled Study. ACR 2014; Boston
88. Papp KA, Leonardi C, Menter A, Ortonne J-P, Krueger JG, Kricorian G et al (2012) Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis. N Engl J Med 366(13):1181–1189
89. Papp K, Leonardi C, Menter A, Thompson EH, Milmont CE, Kricorian G et al (2014) Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 71(6):1183–1190
90. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A et al (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370(24):2295–2306
91. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E et al (2012) Anti–interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366(13):1190–1199
92. Langley RG, Rich P, Menter A, Krueger G, Goldblum O, Dutronc Y et al (2015) Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol JEADV
93. Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73(1):95–100
94. Jimenez-Boj E, Stamm TA, Sadlonova M, Rovensky J, Raffayova H, Leeb B et al (2012) Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 71(11):1868–1871
95. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R et al (2012) Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 167(3):668–677
96. Menter A, Papp KA, Tan H, Tyring S, Wolk R, Buonanno M (2014) Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions. J Drugs Dermatol 13(3):252–256
97. Budamakuntla L, Madaiah M, Sarvajnamurthy S, Kapanigowda S (2015) Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience. Clin Exp Dermatol 40(2):152–155
98. Biggioggero M, Favalli EG (2014) 10-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res 75(Suppl 1):S38–S41